Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 6043 (114th)

Fair Accountability and Innovative Research Drug Pricing Act of 2016

referredUnited States· United States Congress· EN

Introduced

15 September 2016

Last action

15 September 2016 · Introduced

Status

Referred to the House Committee on Energy and Commerce.

Sponsors

Rep. Schakowsky, Janice D. [D-IL-9], Rep. DeLauro, Rosa L. [D-CT-3], Rep. McDermott, Jim [D-WA-7], Rep. Cummings, Elijah E. [D-MD-7], Rep. Kirkpatrick, Ann [D-AZ-2], Rep. Doggett, Lloyd [D-TX-37], Sen. Welch, Peter [D-VT], Rep. Nadler, Jerrold [D-NY-12], Rep. Conyers, John, Jr. [D-MI-13], Rep. Castor, Kathy [D-FL-14], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Blumenauer, Earl [D-OR-3], Rep. Pocan, Mark [D-WI-2], Rep. Yarmuth, John A. [D-KY-3], Rep. Moore, Gwen [D-WI-4], Rep. Lynch, Stephen F. [D-MA-8], Rep. Walz, Timothy J. [D-MN-1], Rep. Lujan Grisham, Michelle [D-NM-1], Rep. Pingree, Chellie [D-ME-1]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Fair Accountability and Innovative Research Drug Pricing Act of 2016 This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency. HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 15 September 2016

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 15 September 2016

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 15 September 2016

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 15 September 2016

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 15 September 2016

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 15 September 2016

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.